Coherus Biosciences, INC 8-K filings

Coherus Oncology announced second quarter 2026 financial results, reporting $13.6 million in LOQTORZI net revenue, a 15% increase from the previous quarter, alongside updates on its clinical pipeline.

Coherus Oncology, Inc. announced on June 12, 2026, the dismissal of Ernst & Young LLP and the appointment of PricewaterhouseCoopers LLP as its new independent registered public accounting firm.

Coherus Oncology's 2026 Annual Meeting saw director elections and compensation approval, with a partial adjournment for a stock option repricing vote.

Coherus Oncology reported Q1 2026 financial results, with LOQTORZI net revenue reaching $11.8 million, alongside updates on clinical trial progress for tagmokitug and casdozokitug.

Coherus Oncology, Inc. announced a clinical supply agreement with Janssen to evaluate tagmokitug in a Phase 1b study for metastatic castration-resistant prostate cancer.

Coherus Oncology, Inc. has filed a prospectus supplement to allow for the potential sale of up to $64.88 million in common stock through an existing sales agreement.

Coherus Oncology, Inc. reported preliminary unaudited net revenues for Q4 and full year 2025, along with cash position, and projected significant growth for its LOQTORZI product.

Coherus Oncology has retrospectively reclassified its biosimilar businesses as discontinued operations following major divestitures, shifting focus to innovative immuno-oncology.

Coherus Oncology reported increased LOQTORZI net revenue and expanded its CHS-114 clinical program to include colorectal cancer in its third quarter 2025 financial results.

Coherus Oncology, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously disclosed deficiency notice.

Coherus Oncology reported a 36% increase in LOQTORZI net revenue for Q2 2025, reaching $10.0 million, alongside strategic debt reduction and extended cash runway through 2026.

Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its common stock trading below the $1.00 minimum bid price requirement, initiating a 180-day compliance period.

Coherus Oncology, Inc. announced that all four proposals, including the election of Class II directors and the ratification of Ernst & Young LLP as independent auditors, were approved by stockholders at its 2025 Annual Meeting.

Coherus BioSciences, Inc. has officially changed its corporate name to Coherus Oncology, Inc., effective May 29, 2025, to reflect its strategic pivot to an exclusive focus on innovative immuno-oncology medicines.

Coherus BioSciences completes strategic transformation to innovative oncology, reporting Q1 2025 financial results with a focus on LOQTORZI and pipeline advancement.

Mark D. Stolper will not seek re-election to the Coherus BioSciences Board of Directors, prompting a reclassification of board member assignments.

Paul Reider, Chief Commercial Officer of Coherus BioSciences, is resigning effective April 30, 2025, following the divestiture of the UDENYCA franchise.

Coherus BioSciences finalizes the sale of its UDENYCA franchise to Intas Pharmaceuticals for $483.4 million upfront, marking a strategic shift towards novel oncology programs.

Coherus BioSciences amends its indenture to facilitate the UDENYCA divestiture and repurchases $170 million of its convertible notes, with plans to repurchase the remaining $60 million after the divestiture closes.

Coherus BioSciences' stockholders have approved the sale of its UDENYCA franchise to Intas Pharmaceuticals at a special meeting held on March 11, 2025.

Coherus BioSciences reports a 4% increase in annual net revenue to $267.0 million for 2024, driven by UDENYCA and LOQTORZI growth, while strategically divesting other assets and focusing on its innovative oncology pipeline.

Coherus BioSciences provides supplemental disclosures to its proxy statement related to the proposed sale of its UDENYCA franchise to Intas Pharmaceuticals in response to stockholder demand letters and lawsuits.

Coherus BioSciences expects 2024 net revenues between $255M and $260M and plans to divest its UDENYCA franchise for up to $558.4M.

Kimberly J. Tzoumakas has resigned from the Board of Directors of Coherus BioSciences, effective December 31, 2024.

Coherus BioSciences will divest its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, allowing Coherus to focus on its immuno-oncology pipeline.

Coherus BioSciences saw a 30% increase in UDENYCA revenue and a 50% increase in LOQTORZI revenue quarter-over-quarter, driving strong overall revenue growth in Q3 2024.

Coherus Biosciences reports a temporary supply interruption of its UDENYCA product due to capacity constraints at its third-party packaging facility, while also outlining long-term supply chain improvements.

Coherus BioSciences announced positive second quarter 2024 financial results, highlighted by a 60% increase in UDENYCA sales compared to the same period last year and the appointment of a new Chief Financial Officer.

Coherus BioSciences has granted Apotex exclusive rights to commercialize toripalimab in Canada, securing an upfront payment and potential future milestone and sales payments.

Coherus BioSciences has sold its YUSIMRY franchise to Hong Kong King-Friend Industrial Company Ltd. for $40 million in an all-cash deal, completed on June 26, 2024.